{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:14:01Z","timestamp":1783426441335,"version":"3.54.6"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>\n                    Prediction of the molecular consequences of missense variants in genetic diseases places a challenge, often resulting in ambiguous classifications by different algorithms. Thus, such variants of unclear significance (VUS) require a thorough molecular characterization to judge if they are pathogenic or not. Pathogenic variants in the\n                    <jats:italic>AGA<\/jats:italic>\n                    gene encoding for aspartylglucosaminidase (AGA) result in aspartylglucosaminuria (AGU), a lysosomal storage disorder. For a correct diagnosis, it is important to understand the effect of VUS found in AGU patients on the structure and function of the AGA enzyme. In this study, several\n                    <jats:italic>AGA<\/jats:italic>\n                    missense variants found in AGU patients were characterized by biochemical and bioinformatics methods. The pathogenicity of most of these variants was verified, but some of them exhibited only a minor pathogenic effect on AGA function. Especially the Leu126Val variant showed a high residual AGA activity, and a homozygous patient with this variant has a mild AGU phenotype with atypical symptoms. In the era of personalized medicine, our data stress the importance of molecular characterization of unclear genetic variants for the choice of best treatment options.\n                  <\/jats:p>","DOI":"10.3389\/fchem.2026.1860625","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:20:05Z","timestamp":1783423205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical characterization of aspartylglucosaminidase missense variants of unclear significance reveals different degrees of functional impairment"],"prefix":"10.3389","volume":"14","author":[{"given":"Antje","family":"Banning","sequence":"first","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille E.","family":"Kreuder","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicara C.","family":"Parr","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Lause","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Voll","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halen","family":"Godany","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ballhausen","sequence":"additional","affiliation":[{"name":"Pediatric Metabolic Unit, Pediatrics, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Faculty of Medicine, University of Giessen","place":["Giessen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.aan6298","article-title":"Lysosomal metabolomics reveals V-Atpase- and mtor-dependent regulation of amino acid efflux from lysosomes","volume":"358","author":"Abu-Remaileh","year":"2017","journal-title":"Sci. (New York, NY)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: a review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3390\/cells10112813","article-title":"Towards splicing therapy for lysosomal storage disorders: methylxanthines and luteolin ameliorate splicing defects in aspartylglucosaminuria and classic late infantile neuronal ceroid lipofuscinosis","volume":"10","author":"Banning","year":"2021","journal-title":"Cells"},{"key":"B4","doi-asserted-by":"publisher","first-page":"37583","DOI":"10.1038\/srep37583","article-title":"Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria","volume":"6","author":"Banning","year":"2016","journal-title":"Sci. Reports"},{"key":"B5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/ijms18040706","article-title":"Functional analysis of the Ser149\/Thr149 variants of human aspartylglucosaminidase and optimization of the coding sequence for protein production","volume":"18","author":"Banning","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.bbadis.2017.12.014","article-title":"Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder aspartylglucosaminuria","volume":"1864","author":"Banning","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms24065722","article-title":"Validation of aspartylglucosaminidase activity assay for human serum samples: establishment of a biomarker for diagnostics and clinical studies","volume":"24","author":"Banning","year":"2023","journal-title":"Int. Journal Molecular Sciences"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/cells14131036","article-title":"Structural and functional characterization of N-Glycanase-1 pathogenic variants","volume":"14","author":"Banning","year":"2025","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/pro.3779","article-title":"Consurf-db: an accessible repository for the evolutionary conservation patterns of the majority of pdb proteins","volume":"29","author":"Ben Chorin","year":"2020","journal-title":"Protein Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","article-title":"Accurate proteome-wide missense variant effect prediction with alphamissense","volume":"381","author":"Cheng","year":"2023","journal-title":"Sci. (New York, NY)"},{"key":"B11","doi-asserted-by":"crossref","first-page":"12105","DOI":"10.1016\/S0021-9258(18)99071-X","article-title":"Characterization of the mutation responsible for aspartylglucosaminuria in three Finnish patients. Amino acid substitution Cys163----Ser abolishes the activity of lysosomal glycosylasparaginase and its conversion into subunits","volume":"266","author":"Fisher","year":"1991","journal-title":"J. Biological Chemistry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3760\/cma.j.cn511374-20220107-00015","article-title":"Analysis of genetic variant in a child with aspartylglucosaminuria","volume":"40","author":"Gao","year":"2023","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chin. Journal Medical Genetics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0883073820980904","article-title":"Aspartylglucosaminuria: clinical presentation and potential therapies","volume":"36","author":"Goodspeed","year":"2021","journal-title":"J. Child Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0331339","DOI":"10.1371\/journal.pone.0331339","article-title":"Computational prediction of high-risk non-synonymous snps in human apoe and their structural impact on amyloid-beta interaction in alzheimer's disease pathogenesis","volume":"20","author":"Hossain","year":"2025","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/j.1460-2075.1991.tb07920.x","article-title":"Aspartylglucosaminuria: cdna encoding human aspartylglucosaminidase and the missense mutation causing the disease","volume":"10","author":"Ikonen","year":"","journal-title":"EMBO Journal"},{"key":"B16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0888-7543(91)90120-4","article-title":"In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation","volume":"11","author":"Ikonen","year":"","journal-title":"Genomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11222","DOI":"10.1073\/pnas.88.24.11222","article-title":"Spectrum of mutations in aspartylglucosaminuria","volume":"88","author":"Ikonen","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells5040045","article-title":"Random splicing of several exons caused by a single base change in the target exon of Crispr\/Cas9 mediated gene knockout","volume":"5","author":"Kapahnke","year":"2016","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/gim.2016.13","article-title":"An openly available online tool for implementing the acmg\/amp standards and guidelines for the interpretation of sequence variants","volume":"18","author":"Kleinberger","year":"2016","journal-title":"Genet. Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-8103849\/v1","article-title":"Pharmacological chaperone treatment with cystadane for aspartylglucosaminuria: an open-label, phase 1b\/2, clinical trial","author":"Laine","year":"2026"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1038\/s41467-025-57757-y","article-title":"Functionally constrained human proteins are less prone to mutational instability from single amino acid substitutions","volume":"16","author":"May","year":"2025","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"Ucsf chimerax: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Science A Publication Protein Soc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1073\/pnas.88.7.2941","article-title":"Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginase","volume":"88","author":"Mononen","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nsb1295-1102","article-title":"Three-dimensional structure of human lysosomal aspartylglucosaminidase","volume":"2","author":"Oinonen","year":"1995","journal-title":"Nat. Structural Biology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0883073812469049","article-title":"Aspartylglucosaminuria: unusual neonatal presentation in Qatari twins with a novel aspartylglucosaminidase gene mutation and 3 new cases in a Turkish family","volume":"29","author":"Opladen","year":"2014","journal-title":"J. Child Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1042\/bj2900735","article-title":"Characterization of three alleles causing aspartylglycosaminuria: two from a British family and one from an American patient","volume":"290","author":"Park","year":"1993","journal-title":"Biochem. Journal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/hmg\/5.6.737","article-title":"Ser72pro active-site disease mutation in human lysosomal aspartylglucosaminidase: abnormal intracellular processing and evidence for extracellular activation","volume":"5","author":"Peltola","year":"1996","journal-title":"Hum. Molecular Genetics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Medicine Official Journal Am. Coll. Med. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/dna.1994.13.257","article-title":"Dissection of the molecular consequences of a double mutation causing a human lysosomal disease","volume":"13","author":"Riikonen","year":"1994","journal-title":"DNA Cell Biology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21340","DOI":"10.1074\/jbc.271.35.21340","article-title":"Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization","volume":"271","author":"Riikonen","year":"1996","journal-title":"J. Biological Chemistry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"W350","DOI":"10.1093\/nar\/gky300","article-title":"Dynamut: predicting the impact of mutations on protein conformation, flexibility and stability","volume":"46","author":"Rodrigues","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"B32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/hmg\/10.9.983","article-title":"Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations","volume":"10","author":"Saarela","year":"2001","journal-title":"Hum. Molecular Genetics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jmd2.12222","article-title":"Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in aspartylglucosaminuria: a case series","volume":"61","author":"Selvanathan","year":"2021","journal-title":"JIMD Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/dna.1995.14.305","article-title":"Intracellular sorting of aspartylglucosaminidase: the role of N-Linked oligosaccharides and evidence of Man-6-P-Independent lysosomal targeting","volume":"14","author":"Tikkanen","year":"1995","journal-title":"DNA Cell Biology"},{"key":"B35","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/j.1460-2075.1996.tb00658.x","article-title":"Functional analyses of active site residues of human lysosomal aspartylglucosaminidase: implications for catalytic mechanism and autocatalytic activation","volume":"15","author":"Tikkanen","year":"1996","journal-title":"EMBO Journal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.1093\/emboj\/16.22.6684","article-title":"Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase","volume":"16","author":"Tikkanen","year":"1997","journal-title":"EMBO Journal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1023\/a:1005371802085","article-title":"Aspartylglucosaminuria among Palestinian arabs","volume":"20","author":"Zlotogora","year":"1997","journal-title":"J. Inherited Metabolic Disease"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1860625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:20:07Z","timestamp":1783423207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1860625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":37,"alternative-id":["10.3389\/fchem.2026.1860625"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1860625","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1860625"}}